AstraZeneca stock jumps 4% after surprise trial win for lung disease drug where rivals have failed

The respiratory treatment Tozorakimab, reduced flare-ups of chronic obstructive pulmonary disease in both former smokers and in the overall population versus placebo, the company said.

“This marks a notable shift in sentiment, given limited conviction in the IL-33 mechanism following prior IL-33 failures from Sanofi and Roche,” said Jefferies analysts.

Tozorakimab and rival drugs belong to a class of treatments called monoclonal antibodies. They work ​by suppressing the action ⁠of the protein interleukin-33 (IL-33) and can reduce inflammation.

London-listed shares were last seen up 3.5% in midday trading, contrasting with the UK’s FTSE 100 index which fell 0.6%.

This is a breaking news story. Please refresh for updates.